NORWOOD, Mass. — Moderna, Inc., the biotechnology company that created one out of several COVID-19 vaccines, announced on Tuesday the expansion of its Moderna Technology Center located in Norwood.
Officials said this expansion includes more than doubling the space to transform the facility from a production and lab space to an industrial technology center.
This will allow the company to increase the production and lab space from approximately 300,000 square feet to 650,000 square feet. There will also be an acquisition of a 240,000 square foot building, expanding its commercial and clinical activities.
“Our manufacturing facility has been core to our long-term strategy and has enabled us to provide the scale and flexibility to support the development of our mRNA medicines and vaccines including our COVID-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We believe that this investment and expansion at our technology center will allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products. As we grow, we are committed to minimizing our environmental footprint.”
Officials added there will be a 50% increase in production of the Moderna COVID-19 vaccine at the company’s manufacturing site. The site will ramp up production in late 2021 and early 2022. Overall, Moderna expects to increase 2022 global capacity by up to 3 billion doses of its COVID-19 vaccine.
Additionally, the company raised its 2021 manufacturing supply forecast to between 800 million to 1 billion doses.
For more information on the expansion and other advancements taking place at Moderna, click here.
Download the free Boston 25 News app for up-to-the-minute push alerts